Tazeen Ahmad
Stock Analyst at B of A Securities
(3.15)
# 1,165
Out of 4,711 analysts
189
Total ratings
45.32%
Success rate
0.71%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Neutral | $26 → $22 | $15.22 | +44.55% | 5 | Dec 19, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $79 → $46 | $6.31 | +629.00% | 3 | Dec 18, 2024 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $22 | $8.36 | +163.16% | 1 | Dec 18, 2024 | |
| PEPG PepGen | Maintains: Neutral | $10 → $6 | $3.63 | +65.29% | 2 | Nov 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $61 → $47 | $33.21 | +41.52% | 6 | Nov 6, 2024 | |
| INCY Incyte | Upgrades: Buy | $68 → $90 | $68.84 | +30.74% | 5 | Oct 30, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $9.80 | +53.06% | 3 | Oct 17, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $307 → $314 | $245.44 | +27.93% | 2 | Oct 14, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Neutral | $48 → $52 | $56.12 | -7.34% | 7 | Oct 14, 2024 | |
| SAGE Sage Therapeutics | Maintains: Underperform | $11 → $6 | $5.61 | +6.95% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $191 | $136.38 | +40.05% | 8 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $113.08 | +32.65% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $4.35 | -54.02% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $29 | $21.45 | +35.20% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 | $41.85 | +81.60% | 4 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $623.82 | -2.70% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $25 → $32 | $46.24 | -30.80% | 15 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $118.97 | +79.04% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $44.22 | +71.87% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $16.87 | +30.41% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.88 | +538.30% | 1 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $2.99 | +368.23% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $5.23 | +91.20% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.68 | +257.14% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $8.50 | +76.47% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $0.5 | $0.98 | -49.04% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $19.57 | -43.79% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $7.57 | +32.10% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $1.96 | +2.04% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.30 | +361.54% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $10.57 | +41.98% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $76.52 | -21.59% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $23 | $0.16 | +13,962.50% | 2 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.69 | +846.75% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $18.48 | +495.24% | 1 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $7.94 | +441.56% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $187.58 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $3.19 | +9,304.39% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $0.96 | +842.31% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $18.98 | +152.90% | 6 | Oct 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $102 | $135.42 | -24.68% | 2 | May 1, 2018 |
Prothena Corporation
Dec 19, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $15.22
Upside: +44.55%
4D Molecular Therapeutics
Dec 18, 2024
Maintains: Buy
Price Target: $79 → $46
Current: $6.31
Upside: +629.00%
KalVista Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $8.36
Upside: +163.16%
PepGen
Nov 18, 2024
Maintains: Neutral
Price Target: $10 → $6
Current: $3.63
Upside: +65.29%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $61 → $47
Current: $33.21
Upside: +41.52%
Incyte
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $68.84
Upside: +30.74%
Amicus Therapeutics
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.80
Upside: +53.06%
Alnylam Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $307 → $314
Current: $245.44
Upside: +27.93%
Rhythm Pharmaceuticals
Oct 14, 2024
Maintains: Neutral
Price Target: $48 → $52
Current: $56.12
Upside: -7.34%
Sage Therapeutics
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $5.61
Upside: +6.95%
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $136.38
Upside: +40.05%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $113.08
Upside: +32.65%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $4.35
Upside: -54.02%
Sep 4, 2024
Maintains: Buy
Price Target: $25 → $29
Current: $21.45
Upside: +35.20%
Jun 25, 2024
Maintains: Buy
Price Target: $76
Current: $41.85
Upside: +81.60%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $623.82
Upside: -2.70%
Jun 21, 2024
Maintains: Underperform
Price Target: $25 → $32
Current: $46.24
Upside: -30.80%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $118.97
Upside: +79.04%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $44.22
Upside: +71.87%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $16.87
Upside: +30.41%
May 8, 2024
Initiates: Buy
Price Target: $12
Current: $1.88
Upside: +538.30%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $2.99
Upside: +368.23%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.23
Upside: +91.20%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.68
Upside: +257.14%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $8.50
Upside: +76.47%
Dec 14, 2023
Downgrades: Underperform
Price Target: $7 → $0.5
Current: $0.98
Upside: -49.04%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $19.57
Upside: -43.79%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $7.57
Upside: +32.10%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $1.96
Upside: +2.04%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.30
Upside: +361.54%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $10.57
Upside: +41.98%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $76.52
Upside: -21.59%
May 27, 2022
Downgrades: Underperform
Price Target: $23
Current: $0.16
Upside: +13,962.50%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.69
Upside: +846.75%
Sep 9, 2021
Initiates: Buy
Price Target: $110
Current: $18.48
Upside: +495.24%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $7.94
Upside: +441.56%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $187.58
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $3.19
Upside: +9,304.39%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $0.96
Upside: +842.31%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $18.98
Upside: +152.90%
May 1, 2018
Maintains: Buy
Price Target: $101 → $102
Current: $135.42
Upside: -24.68%